Elanco Bolstering Portfolio With Planned $885M Acquisition
(Elanco facility image courtesy of Eli Lilly and Co.)
Subscriber Benefit
As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe NowGreenfield-based Elanco U.S. Inc. has announced an agreement to add the companion animal vaccine portfolio of one of its competitors. The $885 million deal with Boehringer Ingelheim Vetmedica Inc. involves dozens of cat, dog and rabies vaccines, as well as an Iowa manufacturing facility. The acquisition is expected to close early next year, pending regulatory approvals.
The deal still requires the blessing of the U.S. Federal Trade Commission. Boehringer Ingelheim will also need to clear antitrust hurdles involving an unrelated deal for assets with Sanofi. Elanco’s current companion animal portfolio includes parasiticides, pain medications and dermatology treatments. The acquisition would add vaccines for conditions such as bordetella, Lyme disease, rabies and parvovirus.
Elanco Animal Health President Jeff Simmons says "we understand the unique bond that owners share with pets and are committed to helping those pets live longer, healthier lives. With a growing portfolio addressing both prevention and treatment of disease, Elanco can partner with veterinarians and pet caregivers to do just that."
The operation included in the agreement is located in Fort Dodge, Iowa, and includes research and development, testing, on-site vet research and laboratory facilities.
You can connect to more about the agreement, including products involved in the deal, by clicking here.